Modulating role of lithium on dopamine turnover, prolactin release, and behavioral supersensitivity following haloperidol and reserpine.
The effects of haloperidol, reserpine, and concomitant lithium were evaluated in biochemical, endocrine, and behavioral studies in the rat. Concomitant administration of a chronic regimen of haloperidol and lithium did not prevent the development of tolerance as noted by dopamine metabolites in the striatum or olfactory tuberculum. Nor did chronic lithium alter behavioral response in rats treated with reserpine and challenged with the dopamine agonist apomorphine. Additionally, prolactin release was increased by haloperidol, but was not altered by acute or chronic lithium treatment. These findings are discussed in the light of present knowledge of pre- and postsynaptic receptor changes and the effects of lithium.
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D004298:Dopamine / Q000378:metabolism*; D004347:Drug Interactions; D006220:Haloperidol / Q000494:pharmacology*; D006719:Homovanillic Acid / Q000378:metabolism; D008094:Lithium / Q000494:pharmacology*; D008297:Male; D011388:Prolactin / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains; D012110:Reserpine / Q000494:pharmacology*
D015102:3,4-Dihydroxyphenylacetic Acid; D012110:Reserpine; D011388:Prolactin; D008094:Lithium; D006220:Haloperidol; D004298:Dopamine; D006719:Homovanillic Acid